FIELD: medicine, neurology.
SUBSTANCE: the present innovation deals with the way for decreasing the disease progressing and/or protecting motor neurons against degeneration and/or protecting against glutamate in patients in case of motor neuron disease (MND). The method includes immunization of the mentioned patients with vaccine that contains copolymer based upon four amino acids tyrosin-glutamate-alanine-lysine Cop-1 as an active agent at dosage being efficient for immunization. Application of the copolymer in question provides the highest activity towards reconstructing motor neurons in such patients.
EFFECT: higher efficiency of therapy.
9 cl, 9 dwg, 8 ex, 6 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| NEW COMBINATIONS OF NERAMEXANE FOR TREATING NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2432161C1 |
| PHARMACEUTICAL COMPOSITION FOR INHIBITING AUTOPHAGY OF MOTOR NEURONS AND USE THEREOF | 2012 |
|
RU2585372C1 |
| USE OF SULPHATE SALTS OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1N-BENZO[D]IMIDAZOL-2-AMINE AND THEIR SOLVATES FOR TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR DISEASES | 2021 |
|
RU2814327C1 |
| HUMANISED ANTIBODY | 2008 |
|
RU2538709C2 |
| USING SEQUENCE CODING C-TERMINAL HEAVY CHAIN DOMAIN OF TETANUS TOXIN AS THERAPEUTIC AGENT | 2008 |
|
RU2495676C2 |
| PREPARATION FROM EGGS WITH REGENERATIVE, ANALGESIC AND ANTI-INFLAMMATORY PROPERTIES | 2012 |
|
RU2585049C2 |
| GENE THERAPY FOR NEURODEGENERATIVE DISORDERS | 2010 |
|
RU2603740C2 |
| APPLICATION OF K-252A DERIVATIVES TO TREAT DISORDERS OF PERIPHERAL OR CENTRAL NERVOUS SYSTEMS AND EXCESSIVE CYTOKINE OUTPUT | 1997 |
|
RU2183959C2 |
| COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DISTURBANCES | 2005 |
|
RU2387453C2 |
| GENE THERAPY OF NEURODEGENERATIVE DISORDERS | 2010 |
|
RU2743398C2 |
